Tagged with TEVA

Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…

Turkey Despite the sharp decline in the Turkish lira’s value, the general mood among pharmaceutical executives in Turkey is positive. Rather than being discouraged, they are calling upon their resiliency and experience from former periods of economic fluctuation to push the Turkish healthcare and life sciences sector forward.   Turkey made…

Turkey Tahsin Yüksel, general manager of Teva Turkey, analyzes the strategic importance of pharmaceutical branding in Turkey, shares the story of Teva’s adaptation to the unique market needs, and offers his insight of what can be expected of the industry in the wake of the country’s current economic hardships.   It…

Portugal Mario Madeira, general manager of Teva Portugal, highlights the milestones of the affiliate in Portugal, referencing the economic crisis and where Teva is now positioned in the country. In addition, he comments on Portugal’s great potential for digitalizing its healthcare sector. What are Teva Portugal’s priorities for 2018? “Teva is…

Spain Carlos Teixeira, CEO of Teva Spain and Portugal, discusses the challenges the generic sector is facing in Spain, which ultimately spurred the company towards other business opportunities, and highlights the significant footprint of the Spanish affiliate, with its manufacturing site in Zaragoza serving as an export base for Europe and…

Poland The Top 20 pharma companies in the Polish retail market for 2017 ranked by sales in USD millions. Domestic champion Polpharma leads the way, followed by international players Teva and Bayer.

Latvia The top 20 companies in the Latvian pharmaceutical market for 2017, sorted by total value and market share, with data on year-on-year growth. American giant AbbVie ranks first, with an almost six percent market share and astounding 65 percent year-on-year growth, followed by TEVA and Sanofi.

Baltics Janis Meiksans, general manager at TEVA Baltics, explains how the base of the company’s success is what they call ‘generic evangelism’ and how from being a marketing and distribution organization in the region, they successfully managed to rank number one pharmaceutical company by sales. Janis, can you talk our international…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Lithuania Audrius Tutlys, country manager at Teva Lithuania, highlights the importance of Teva in Lithuania, based not only on its broad product offering but also its manufacturing capabilities and shares his willingness to position Teva as a true partner of the government in making Lithuania a European biotech center. Can you…

Canada Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and the critical importance of Canada possessing a local pharma manufacturing industry. Teva recently announced a new global CEO, Kåre Schultz.…

Bulgaria Nikolay Hadjidontchev, general manager at Actavis EAD – a Teva company (the sales and marketing part of the company) in Bulgaria, explains the importance of finding the right balance between innovative and generic portfolios and highlights the unique positioning of Teva in Bulgaria as a consequence of the global acquisition…